Skip to main content

Lupus

      9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylate

      Peter Nash drpnash

      1 year 3 months ago
      9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylated cd20 @rheumnow #EULAR2024
      #EULAR2024 POS0024 Lymphopenia, anemia, & low Plt are assoc with disease activity & damage accrual in #lupus. Po

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      #EULAR2024 POS0024 Lymphopenia, anemia, & low Plt are assoc with disease activity & damage accrual in #lupus. Post-hoc analysis of RCTs + LTE showed Anifrolumab normalised these Haem parameters vs PBO. May improve fatigue-associated with anaemia @RheumNow https://t.co/GF8aKU0Z5x
      SLE Preview: abolishing refractory with CAR-T and better B-cell therapies

      Despite advancements, some SLE patients rema

      Dr. John Cush RheumNow

      1 year 3 months ago
      SLE Preview: abolishing refractory with CAR-T and better B-cell therapies Despite advancements, some SLE patients remain refractory to belimumab and off-label rituximab, the main B cell-targeted therapies in the last 15 years. https://t.co/778buNUq1C https://t.co/4ub8VbrLb6
      With a better understanding of pathophysiology, improved management guidelines, available medications, and a multidisciplinary approach, pregnancy for lupus patients has become more feasible. Despite these improvements, some patients still experience poor outcomes, highlighting the need for biomarkers that can predict these risks. An abstract presented at #EULAR2024 (POS1393) explored this possibility.
      #EULAR2024 POS0257 One for the future. Phase 2A RCT showed KPG-818, a Novel Cereblon Modulator (targets Aiolos & Ika

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      #EULAR2024 POS0257 One for the future. Phase 2A RCT showed KPG-818, a Novel Cereblon Modulator (targets Aiolos & Ikaros) was well tolerated with efficacy signal (SLEDAI-2K & CLASI-50). Effect and safety profile were numerically better in the lowest dose @RheumNow https://t.co/Bjk9zBRmVo
      🧠POS0730 Self-reported cognitive function in older adults with #SLE in @ndb_org registry

      ➡️Cognitive symptoms si

      Mrinalini Dey DrMiniDey

      1 year 3 months ago
      🧠POS0730 Self-reported cognitive function in older adults with #SLE in @ndb_org registry ➡️Cognitive symptoms significantly worse in older people w SLE vs other #RMDs ➡️Perceptions of cognitive function assoc with less satisfaction with health & ⬇️ #QoL @RheumNow #EULAR2024
      #EULAR2024 POS0529 Post-hoc analysis from Phase 2 NOBILITY showed consistent renal response was achieved in Obinutuzumab

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      #EULAR2024 POS0529 Post-hoc analysis from Phase 2 NOBILITY showed consistent renal response was achieved in Obinutuzumab + SOC vs PBO + SOC across Complete Renal Response definitions and baseline Proteinuria levels. Assuring and looking forward to results next year @RheumNow https://t.co/wKCOP5BgoQ
      #SARD #ILD
      Who to screen for #rheumatic #diseases
      For
      ILD

      #ACR guidelines

      Screening May also depend on ILD prevale

      Janet Pope Janetbirdope

      1 year 3 months ago
      #SARD #ILD Who to screen for #rheumatic #diseases For ILD #ACR guidelines Screening May also depend on ILD prevalence Not sure if frequency of screening and how to screen @jeffsparks #ORA24 @ORAexec https://t.co/BcyyYLKvr6
      ×